- Recent Funding
- Investors
- Enavate Sciences
Enavate Sciences portfolio
Enavate Sciences has 1 portfolio company on record at Recent Funding. Its most recent investment on record is Normunity's $75M Series B+ round in January 2025, which it led, alongside YK Bioventures, Taiho Ventures, Sanofi Ventures and 6 others. That company is in Health and bio.
What Enavate Sciences invests in
- Health and bio · 1 · 100%
How Enavate Sciences invests
| Stage | Deals | Capital in rounds |
|---|---|---|
| Series B+ | 1 100% | $75M |
Share is of the 1 round on Recent Funding that name Enavate Sciences. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.
Enavate Sciences portfolio companies
NNormunity$75MSeries B+ · Jan 2025
| Company | Round with Enavate Sciences | Total raised | Latest raise |
|---|---|---|---|
Health and bio |
Series B+ · $75M · lead | $140M | Jan 13, 2025 Series B+ |
Most frequent co-investors
RRegeneron Ventures1 shared round · last Jan 13, 2025
SSanofi Ventures1 shared round · last Jan 13, 2025
HHSG1 shared round · last Jan 13, 2025
SSamsara Biocapital1 shared round · last Jan 13, 2025
CConnecticut Innovations1 shared round · last Jan 13, 2025
YYK Bioventures1 shared round · last Jan 13, 2025
TTaiho Ventures1 shared round · last Jan 13, 2025
PPfizer Venture Investments1 shared round · last Jan 13, 2025
OOsage Venture Partners1 shared round · last Jan 13, 2025
Similar investors
AAccelia Capital1 company · 1 deal in 12 mo
BBioGenerator Ventures1 company · 1 deal in 12 mo
BBiospring Partners1 company · 1 deal in 12 mo
CColossa Ventures1 company · 1 deal in 12 moFFirst Imagine!1 company · 1 deal in 12 mo
MMaxis1 company · 1 deal in 12 mo
Investors whose portfolios on Recent Funding center on the same category (Health and bio).
Portfolio companies are the companies on Recent Funding with a round that lists Enavate Sciences, which is a subset of its real portfolio. API: /api/v1/investors/enavate-sciences (get a free API key). More: the most active VC firms and new venture capital funds.